Ads
related to: g1 well differentiated neuroendocrine tumor treatment- GIST Resistance
Learn more about the complexity of
GIST and a treatment option.
- Access Assistance
Find services and solutions to help
get your patients started faster.
- Distribution Fact Sheet
A resource with info about
treatment distribution.
- Dosing Information
Learn more about dosing
information for your patients.
- Request Educational Info
Request patient educational
materials and more.
- Patient Education
A patient and care partners guide
with treatment information.
- GIST Resistance
Search results
Results From The WOW.Com Content Network
well-differentiated neuroendocrine tumors, further subdivided into tumors with benign and those with uncertain behavior; well-differentiated (low grade) neuroendocrine carcinomas with low-grade malignant behavior; poorly differentiated (high grade) neuroendocrine carcinomas, which are the large cell neuroendocrine and small cell carcinomas.
The European Commission approved lutetium (177 Lu) oxodotreotide (brand name Lutathera) "for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults" in September 2017.
The new 2019 WHO classification and grading criteria for neuroendocrine tumors of the digestive system grades all the neuroendocrine tumors into three grades, based on their degree of cellular differentiation (from well-differentiated NET grade (G)1 to G3, and poorly-differentiated neuroendokrina cancer, NEC G3), morphology, mitotic rate and Ki ...
Tumors may be graded on four-tier, three-tier, or two-tier scales, depending on the institution and the tumor type. The histologic tumor grade score along with the metastatic (whole-body-level cancer-spread) staging are used to evaluate each specific cancer patient, develop their individual treatment strategy and to predict their prognosis.
The immunohistochemical phenotype of focal neuroendocrine differentiation in prostate cancer has been intensively studied. Chromogranin A, which is the most abundant product of prostatic neuroendocrine cells and neuroendocrine tumor cells, is widely recognized as a reliable marker for neuroendocrine differentiation. [4]
The 2010 WHO classification of tumors of the digestive system grades all the pancreatic neuroendocrine tumors (PanNETs) into three categories, based on their degree of cellular differentiation (from "NET G1" through to the poorly differentiated "NET G3"). [24]
Ads
related to: g1 well differentiated neuroendocrine tumor treatment